Orietta Picconi

List of Publications by Year
in descending order

39 papers	2,156 citations	566801 15 h-index	377514 34 g-index
39 all docs	39 docs citations	39 times ranked	3040 citing authors

#	Article	IF	Citations
1	Kaposiâ€™s Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies. International Journal of Molecular Sciences, 2022, 23, 2081.	1.8	0
2	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.. EBioMedicine, 2021, 66, 103306.	2.7	11
3	Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy. Journal of Personalized Medicine, 2021, 11, 756.	1.1	10
4	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology, 2021, 166, 2955-2974.	0.9	6
5	A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. European Review for Medical and Pharmacological Sciences, 2021, 25, 3316-3324.	0.5	10
6	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. International Journal of Molecular Sciences, 2021, 22, 317.	1.8	12
7	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. Molecular Cancer Therapeutics, 2020, 19, 2476-2489.	1.9	5
8	High HIV-1 diversity in immigrants resident in Italy (2008â€“2017). Scientific Reports, 2020, 10, 3226.	1.6	8
9	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	2.0	12
10	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines, 2019, 7, 99.	2.1	14
11	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Frontiers in Immunology, 2019, 10, 233.	2.2	23
12	Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. Frontiers in Oncology, 2019, 9, 1245.	1.3	6
13	The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Experimental Hematology, 2017, 50, 53-76.	0.2	12
14	â€œcART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studiesâ€• Expert Review of Vaccines, 2017, 17, 1-12.	2.0	4
15	CALR resets the stress-response of erythroid cells and this function is impaired by CALR and JAK2 mutations alike in MPN. Experimental Hematology, 2016, 44, S70.	0.2	0
16	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	0.9	33
17	Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study. Journal of Dermatological Treatment, 2016, 27, 399-405.	1.1	4
18	Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. Blood, 2016, 128, 399-399.	0.6	0

#	Article	IF	Citations
19	The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. Blood, 2016, 128, 545-545.	0.6	0
20	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015, 12, 33.	0.9	55
21	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opinion on Biological Therapy, 2015, 15, 13-29.	1.4	19
22	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 321-6.	0.2	0
23	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. PLoS ONE, 2014, 9, e95183.	1.1	3
24	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	0.9	48
25	Subcutaneous Interferon Î²-1a May Protect against Cognitive Impairment in Patients with Relapsingâ€“Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	1.1	53
26	Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social Life. Acta Dermato-Venereologica, 2012, 92, 299-303.	0.6	132
27	Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq1 1 0.784314 rgBT/Overlock	1.1	43
28	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	1.1	56
29	BDNF Val66Met polymorphism and brain volumes in multiple sclerosis. Neurological Sciences, 2011, 32, 117-123.	0.9	21
30	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon Î²-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	0.8	11
31	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. Journal of Translational Medicine, 2011, 9, 42.	1.8	10
32	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.4	43
33	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. PLoS ONE, 2010, 5, e13540.	1.1	94
34	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€”remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77.	1.4	89
35	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€“remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	1.4	172
36	Development of the Italian Version of the National Institutes of Health Stroke Scale. Stroke, 2009, 40, 2557-2559.	1.0	27

#	Article	IF	Citations
37	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingâ€”remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77.	1.5	11
38	Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer, 2005, 41, 45-60.	1.3	1,024
39	Evidence for the Association of Human Papillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals. Archives of Dermatology, 2003, 139, 890-4.	1.7	109